Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
63 recruiting
Showing 1–20 of 62 trials
Recruiting
Phase 3
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled192 locationsNCT07195695
Recruiting
Phase 2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Pulmonary Hypertension
Pfizer36 enrolled36 locationsNCT07073820
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled195 locationsNCT06793215
Recruiting
Phase 3
IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc.600 enrolled42 locationsNCT07217301
Recruiting
Phase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Pulmonary Disease, Chronic Obstructive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 enrolled29 locationsNCT07252908
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Carcinoma, Non-Small Cell Lung
Hoffmann-La Roche800 enrolled36 locationsNCT06862869
Recruiting
Phase 3
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
Akeso560 enrolled53 locationsNCT07010263
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Pfizer252 enrolled125 locationsNCT06977581
Recruiting
Phase 1
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Advanced Solid TumorMalignant MesotheliomaMetastatic Malignant Solid Tumor
InSilico Medicine Hong Kong Limited100 enrolled10 locationsNCT06566079
Recruiting
Phase 2
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Unresectable Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China43 enrolled1 locationNCT07408635
Recruiting
Phase 2
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
NSCLC Stage IINSCLC Stage III
Shanghai Pulmonary Hospital, Shanghai, China54 enrolled1 locationNCT07410975
Recruiting
Phase 2
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.66 enrolled18 locationsNCT06924606
Recruiting
Phase 1
First in Human Study of SIM0610 in Solid Tumors
Colorectal, CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more
Jiangsu Simcere Pharmaceutical Co., Ltd.260 enrolled7 locationsNCT07348211
Recruiting
Phase 2
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Non-small Cell Lung Cancer
Shanghai Henlius Biotech60 enrolled1 locationNCT07269782
Recruiting
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China250 enrolled1 locationNCT07328945
Recruiting
Phase 2
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China36 enrolled1 locationNCT07323056
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled244 locationsNCT05899608
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340